Navigation Links
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Date:6/26/2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
2. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
3. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
4. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
5. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
6. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Moffitt researcher publishes book on nutritional management of cancer treatment effects
10. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
11. Moffitt Cancer Center researchers working at frontiers of melanoma research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... Ohio (PRWEB) , ... December 07, 2016 , ... ... in the 2016 BOC Business Brilliance Awards under the Best New Product Launch ... and results achieved through user experience. , BOC Global Events & Training Group ...
(Date:12/7/2016)... ... 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but ... presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of published ... for this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the fifth annual Business Architecture Innovation Summit in Reston, VA on March 21-22, ... who will share a range of experiences from a cross-section of industries such ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... networks that can be seen on a type of MRI, according to a ... progressive disorder of the central nervous system characterized by tremors or trembling and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... bringing their 100% all-natural lice removal service to Brooklyn ... th Street was specifically chosen to make treatment convenient for ... is to ease parents, stress and bring their lives back under ... to class without skipping a beat. The best part is that ... family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... LONDON , Dec. 6, 2016 Diabetes ... The diabetes and obesity disease cluster is currently ... (T1DM) and type 2 diabetes mellitus (T2DM), and the ... and quality of products, is attributable to these indications. ... a large market presence, there are a large number ...
(Date:12/6/2016)... , Dec. 6, 2016 Human Vaccines ... in-depth region wise and country wise analysis of ... include manufacturers of human vaccines products, raw material ... to enter the market. The report provides ... vaccines market. Qualitative analysis comprises market dynamics, trends, ...
Breaking Medicine Technology: